» Articles » PMID: 28688220

Assessment of the Protein Interaction Between Coagulation Factor XII and Corn Trypsin Inhibitor by Molecular Docking and Biochemical Validation

Overview
Publisher Elsevier
Specialty Hematology
Date 2017 Jul 9
PMID 28688220
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Summary: Background Corn trypsin inhibitor (CTI) has selectivity for the serine proteases coagulation factor XII and trypsin. CTI is in widespread use as a reagent that specifically inhibits the intrinsic pathway of blood coagulation but not the extrinsic pathway. Objectives To investigate the molecular basis of FXII inhibition by CTI. Methods We performed molecular docking of CTI, using its known crystal structure, with a model of the activated FXII (FXIIa) protease domain. The interaction model was verified by use of a panel of recombinant CTI variants tested for their ability to inhibit FXIIa enzymatic activity in a substrate cleavage assay. Results The docking predicted that: (i) the CTI central inhibitory loop P1 Arg34 side chain forms a salt bridge with the FXIIa S1 pocket Asp189 side chain; (ii) Trp22 from CTI helix α1 interacts with the FXIIa S3 pocket; and (iii) Arg43 from CTI helix α2 forms a salt bridge with FXIIa H1 pocket Asp60A. CTI amino acid substitution R34A negated all inhibitory activity, whereas the G32W, L35A, W22A and R42A/R43A substitutions reduced activity by large degrees of 108-fold, 41-fold, 158-fold, and 100-fold, respectively; the R27A, W37A, W39A and R42A substitutions had no effect. Synthetic peptides spanning CTI residues 20-44 had inhibitory activity that was three-fold to 4000-fold less than that of full-length CTI. Conclusions The data confirm the validity of a canonical model of the FXIIa-CTI interaction, with helix α1 (Trp22), central inhibitory loop (Arg34) and helix α2 (Arg43) of CTI being required for effective binding by contacting the S1, S3 and H1 pockets of FXIIa, respectively.

Citing Articles

6-(Arylaminomethyl) Isoquinolines as Enzyme Inhibitors and Their Preparation: A Patent Highlight of Factor XIIa Inhibitors.

Al-Horani R Cardiovasc Hematol Agents Med Chem. 2023; 21(3):243-249.

PMID: 36703578 PMC: 10501477. DOI: 10.2174/1871525721666230126114224.


Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability.

Abu-Fanne R, Stepanova V, Litvinov R, Abdeen S, Bdeir K, Higazi M Blood. 2018; 133(5):481-493.

PMID: 30442678 PMC: 6356988. DOI: 10.1182/blood-2018-07-861237.


Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo.

Zilberman-Rudenko J, Reitsma S, Puy C, Rigg R, Smith S, Tucker E Arterioscler Thromb Vasc Biol. 2018; 38(8):1748-1760.

PMID: 30354195 PMC: 6205188. DOI: 10.1161/ATVBAHA.118.311193.


Contact Pathway Function During Human Whole Blood Clotting on Procoagulant Surfaces.

Zhu S, Herbig B, Yu X, Chen J, Diamond S Front Med (Lausanne). 2018; 5:209.

PMID: 30083534 PMC: 6064720. DOI: 10.3389/fmed.2018.00209.


An update on factor XI structure and function.

Mohammed B, Matafonov A, Ivanov I, Sun M, Cheng Q, Dickeson S Thromb Res. 2017; 161:94-105.

PMID: 29223926 PMC: 5776729. DOI: 10.1016/j.thromres.2017.10.008.


References
1.
Krupka J, May F, Weimer T, Pragst I, Kleinschnitz C, Stoll G . The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats. PLoS One. 2016; 11(1):e0146783. PMC: 4731395. DOI: 10.1371/journal.pone.0146783. View

2.
Spraggon G, Phillips C, Nowak U, Ponting C, Saunders D, Dobson C . The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure. 1995; 3(7):681-91. DOI: 10.1016/s0969-2126(01)00203-9. View

3.
Lei M, Reeck G . Combined use of trypsin-agarose affinity chromatography and reversed-phase high-performance liquid chromatography for the purification of single-chain protease inhibitor from corn seeds. J Chromatogr. 1986; 363(2):315-21. DOI: 10.1016/s0021-9673(01)83751-1. View

4.
Pathak M, Wilmann P, Awford J, Li C, Hamad B, Fischer P . Coagulation factor XII protease domain crystal structure. J Thromb Haemost. 2015; 13(4):580-91. PMC: 4418343. DOI: 10.1111/jth.12849. View

5.
Silverberg M, Dunn J, Garen L, Kaplan A . Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem. 1980; 255(15):7281-6. View